IL6 and metabolic dysfunction-associated steatohepatitis: More recently, the effects of Rifaximin, a broad spectrum gut bacteria antibiotic, was examined in biopsy-proven NASH patients and found to reduce serum endotoxins as well as IL-6 concentrations [27].